Antifungal resistance in Aspergillus

References

• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi: approved standard [NCCLS document M38-A]. National Committee for Clinical Laboratory Standards, Wayne, PA 2002
   Google Scholar
• Gardiner RE, Park S, Soteropoulos P, Perlin DS. Characterization of Aspergillus fumigatus mutants with reduced susceptibility to caspofungin. Med Mycol. 2005; 43((suppl 1))S299–S305
   Google Scholar
• Dannaoui E, Persat F, Monier MR, Borel E, Piens MA, Picot S. In vitro susceptibility of Aspergillus supp. Isolates amphotericin B and itraconazole. J Antimicriob Chemother 1999; 44: 553–555
   PubMed Web of Science ®Google Scholar
• Verweij PE, Te Dorsthorst DT, Rijs AJ, DeVries-Hospers HG, Meis JF. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002; 40: 2648–2650
   PubMed Web of Science ®Google Scholar
• Balajee SA, Weaver N, Imhof A, Gribskov J, Marr KA. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004; 48: 1197–1203
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Borel E, Monier MF, Piens NA, Picot S, Persat F. Acquired itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother 2001; 47: 333–340
   PubMed Web of Science ®Google Scholar
• Denning DW, Venkateswarlu K, Oakley KL, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364–1368
   PubMed Web of Science ®Google Scholar
• Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46: 556–557
   PubMed Web of Science ®Google Scholar
• Oakley KL, Morrissey G, Denning DW. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant is of Aspgerillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1504–1507
   PubMed Web of Science ®Google Scholar
• Warris A, Weemaes CM, Verweij PE. Multidrug resistance in Aspergillus fumigatus. N Engl J Med 2002; 347: 2173–2174
   PubMed Web of Science ®Google Scholar
• Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: 950–952
   PubMed Web of Science ®Google Scholar
• Siwek GT, Dodgson KJ, De Magahaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receives voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584–587
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743–746
   PubMed Web of Science ®Google Scholar
• Sutton DA, Sanche SE, Revankar SG, Fothergill AQ, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, a head-to-head comparison of voriconazole. Clin Infect Dis 2004; 39: 743–746
   Google Scholar
• Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenes and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188: 305–319
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of cases. Clin Infect Dis 2004; 39: 192–198
   PubMed Web of Science ®Google Scholar
• Chandrasekar PH, Cutright JL, Manavathu EK. Aspergillus: rising frequency of clinical isolation and continued susceptibility antifungal agents, 1994–1999. Diagn Microbiol Infect Dis 2001; 41: 211–214
   PubMed Web of Science ®Google Scholar
• Sutton, DA, Sothergill, QA, Rinaldi, MF. Aspergillus, in vitro antifungal susceptibility data: new millennium trends. Advances Against Aspergillosis, San Francisco, Sept 9–11, 2004: Abst #16.
   Google Scholar
• Manavathu, EK, Cutright, JL, Chandrasekar, PH. In vivo resistance to amphotericin B of a laboratory-selected Aspergillus fumigatus isolate. Antimicrob Agents Chemother, (In Press).
   Google Scholar
• Kontoyiannis DP, Lewis RE, Sagar N, May G, Prince RA, Rolston KV. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test based strategy. Antimicrob Agents Chemother 2000; 44: 2915–2918
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Kofler G, Kropshofer G, et al. In vitro testing of susceptibility of amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 1998; 42: 497–502
   PubMed Web of Science ®Google Scholar
• Moosa MY, Alangaden GJ, Manavathu EK, Chandrasekar PH. Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis. J Antimicrob Chemother 2002; 49: 209–213
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meletiadis J, Tortorano AM, et al. Susceptibility testing of sequential isolates of Aspergillus fumigatus recover from treated patients. J Med Microbiol 2004; 53: 129–134
   PubMed Web of Science ®Google Scholar